



# The Cancerguard® Test: A Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing


## The critical need for MCED testing<sup>1,2</sup>



## The Cancerguard test: Expanding cancer detection beyond a single organ<sup>4,5</sup>




## How the Cancerguard test works: A multi-biomarker class approach to improve detection potential, especially in early stages<sup>7,8</sup>



Based on a stratified case-control test development study; distributions of cancer types and stages are not fully representative of the intended use population. Results do not reflect expected real-world test performance. \*Excluded 88 breast and 51 prostate cancers. The Cancerguard test is not indicated for the screening of breast and prostate cancer. Sensitivity for all cancers is 57.8% (95% CI: 54.1%-61.3%). †Refers to those cancers with the shortest 5-year survival rates: esophagus, liver, lung, ovarian, pancreatic, stomach.

## Diagnostic resolution pathway<sup>‡</sup> after a positive test, designed for accuracy, reliability, and efficiency<sup>9,10</sup>




Imaging resolution workflow is based on published expert clinician opinion and results from an exploratory, prospective, interventional study. There are no established guidelines for imaging following a positive Cancerguard test result. Providers should use their clinical judgment and experience when deciding how to diagnose or treat patients. ‡This test is not meant to replace clinical standard of care. Suggested pathways are intended to encourage clinicians to ask questions and consider important factors as they define the ideal diagnostic strategy for their patients.


**Disclaimer:** The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.

# Care Navigation for the Cancerguard® Test

## Cancerguard® Flexible Blood Collection Options



## Supporting Patients After a Positive Test Result



<sup>§</sup>Patients must apply. Eligibility depends on program qualifications (which are subject to change) and is not guaranteed. The program will not reimburse any covered imaging costs, including copay, coinsurance, and/or deductible amounts determined by insurance.



Scan to visit the website for test results and additional information

**CI:** confidence interval; **CT:** computed tomography; **ct-DNA:** circulating tumor DNA; **18F-FDG PET-CT:** fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography; **MCED:** multi-cancer early detection; **MSLs:** medical science liaisons; **USPSTF:** U.S. Preventive Services Task Force.

**1.** Siegel RL, et al. *CA Cancer J Clin.* 2026;e70043. **2.** USPSTF. A & B Recommendations. Published 2022. Accessed April 10, 2026. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations> **3.** Data on file. Cancers without USPSTF recommended screening. 2026. Medical Affairs, Abbott, Madison, WI. **4.** Ahlquist DA. *NPJ Precis Oncol.* 2018;2:23. **5.** Cancerguard Clinician Brochure. Exact Sciences Corporation. Madison, WI. **6.** Data on File. Cancerguard cancer subtype analysis. [MED-REF-01259]. Exact Sciences. Madison, WI; September 2025. **7.** Gainullin VG, et al. The complementary contributions of methylation and protein biomarker classes in a multi-cancer early detection (MCED) test. Poster 1109 presented at AACR 2026 April 17-22, 2026, in San Diego, CA. **8.** Gainullin VG, et al. *medRxiv.* 2026. doi: <https://doi.org/10.64898/2026.03.03.26347329> **9.** Kisiel J, et al. *Life (Basel).* 2024;14(8):925. **10.** Tyson C, et al. Evaluating the diagnostic burden of tumor localization strategies for multi-cancer early detection tests. Abstract 769 presented at AACR 2023 April 14-19, 2023, Orlando FL, USA.